Zaltrap Union européenne - hongrois - EMA (European Medicines Agency)

zaltrap

sanofi winthrop industrie - aflibercept - colorectalis daganatok - daganatellenes szerek - metasztatikus colorectalis rák (mcrc) kezelése.

Kevzara Union européenne - hongrois - EMA (European Medicines Agency)

kevzara

sanofi winthrop industrie - sarilumab - arthritis, rheumatoid - immunszuppresszánsok - kevzara metotrexát (mtx) kombinálva javallt a kezelés a közepesen súlyos, aktív rheumatoid arthritis (ra) felnőtt betegeknél, akik reagáltak a nem megfelelően, vagy akik intoleráns, anti reumás módosítása egy vagy több betegség betegségmódosító antireumatikus szerek. a kevzara monoterápiaként adható mtx-expozíció esetén, vagy ha az mtx-kezelés nem megfelelő.

Dupixent Union européenne - hongrois - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatitisellenes szerek, a kortikoszteroidok kivételével - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Insulin lispro Sanofi Union européenne - hongrois - EMA (European Medicines Agency)

insulin lispro sanofi

sanofi winthrop industrie - lispro inzulin - diabetes mellitus - cukorbetegségben szedett gyógyszerek - a felnőttek és a gyermekek a cukorbetegség kezelésére, akiknek szükségük van a normális glükóz-homeosztázis fenntartásához az inzulin. a lispro sanofi inzulin a cukorbetegség kezdeti stabilizálására is fel van tüntetve.

Insulin aspart Sanofi Union européenne - hongrois - EMA (European Medicines Agency)

insulin aspart sanofi

sanofi winthrop industrie - aszpart inzulin - diabetes mellitus - cukorbetegségben szedett gyógyszerek - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Truvelog Mix 30 Union européenne - hongrois - EMA (European Medicines Agency)

truvelog mix 30

sanofi winthrop industrie - aszpart inzulin - diabetes mellitus - cukorbetegségben szedett gyógyszerek - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.